Healthcare -
Biotechnology - NASDAQ - US
$ 1.125
-1.82 %
$ 3.31 M
Market Cap
None
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CNS Pharmaceuticals, Inc.
| Net Income | -14.9 M |
| Depreciation & Amortization | 3.31 K |
| Capital Expenditures | -4.19 K |
| Stock-Based Compensation | 839 K |
| Change in Working Capital | -3.69 M |
| Others | 536 K |
| Free Cash Flow | -17.1 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||
| Net Income | (14.9) | (18.9) | (15.3) | (14.0) | (9.5) | (3.9) | (7.4) | (0.2) |
| Depreciation & Amortization | 3.31 K | 4.13 K | 11.8 K | 13.1 K | 11.1 K | 1.96 K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | (0.7) | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 0.8 | 1.0 | 1.2 | 1.7 | 1.3 | 0.5 | 0.1 | 0.1 |
| Other Operating Activities | 0.6 | 498 | 0.3 | 0.7 | 1.58 K | 0.3 | 6.5 | 2.42 K |
| Change in Working Capital | (3.7) | 3.7 | 3.2 | (1.2) | 0.8 | (0.4) | 83.8 K | 47.2 K |
| Cash From Operations | (17.1) | (14.1) | (10.6) | (13.5) | (7.3) | (3.6) | (0.7) | (0.1) |
| INVESTING CASH FLOW | ||||||||
| Capital Expenditures | 4.19 K | 3.9 K | 4.42 K | 5.75 K | 17.9 K | 20.1 K | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 4.19 K | 3.9 K | 4.42 K | 5.75 K | 17.9 K | 20.1 K | 0 | 0 |
| FINANCING CASH FLOW | ||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (0.3) | (0.4) | 0 | 0 | 43.1 K | 35 K | 0.3 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 45.4 K | 2.8 | 15.6 | 4.5 | 45 K | 0 | 0.9 | 0.2 |
| Cash From Financing Activities | 23.0 | 4.6 | 15.6 | 4.5 | 14.1 | 10.3 | 1.2 | 0.2 |
| CHANGE IN CASH | ||||||||
| Net Change In Cash | 5.9 | (9.5) | 5.1 | (9.0) | 6.8 | 6.7 | 0.4 | 0.1 |
| FREE CASH FLOW | ||||||||
| Free Cash Flow | (17.1) | (14.1) | (10.6) | (13.5) | (7.3) | (3.6) | (0.7) | (0.1) |